Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy

Cancer testis antigens (CTAs) are promising cancer associated antigens in solid tumors, but in acute myeloid leukemia, dense promoter methylation silences their expression. Leukemia cell lines exposed to HMAs induce expression of CTAs. We hypothesized that AML patients treated with standard of care decitabine (20mg/m2 per day for 10 days) would demonstrate induced expression of CTAs. Peripheral blood blasts serially isolated from AML patients treated with decitabine were evaluated for CTA gene expression and demethylation. Induction of NY-ESO-1 and MAGEA3/A6, were observed following decitabine. Re-expression of NY-ESO-1 and MAGEA3/A6 was associated with both promoter specific and global (LINE-1) hypomethylation. NY-ESO-1 and MAGEA3/A6 mRNA levels were increased irrespective of clinical response, suggesting that these antigens might be applicable even in patients who are not responsive to HMA therapy. Circulating blasts harvested after decitabine demonstrate induced NY-ESO-1 expression sufficient to activate NY-ESO-1 specific CD8+ T-cells. Induction of CTA expression sufficient for recognition by T-cells occurs in AML patients receiving decitabine. Vaccination against NY-ESO-1 in this patient population is feasible.

[1]  Austin Miller,et al.  Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old , 2015, American journal of hematology.

[2]  H. Deeg.  Treatment ethics, quality of life and health economics in the management of hematopoietic malignancies in older patients , 2015, Bone Marrow Transplantation.

[3]  M. Treppendahl,et al.  Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation , 2015, Oncotarget.

[4]  B. Paluch,et al.  Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts , 2015, Epigenetics.

[5]  M. Carroll,et al.  CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia , 2015, Leukemia.

[6]  Sadik H. Kassim,et al.  A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response , 2014, Clinical Cancer Research.

[7]  J. Karbach,et al.  Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. , 2014, Leukemia research.

[8]  N. Kröger,et al.  Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis , 2014, Leukemia.

[9]  C. Blank,et al.  Interferon‐induced programmed death‐ligand 1 (PD‐L1/B7‐H1) expression increases on human acute myeloid leukemia blast cells during treatment , 2014, European journal of haematology.

[10]  D. Bonnet,et al.  Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo , 2014, Leukemia.

[11]  L. Harlan,et al.  Treatment of de novo acute myeloid leukemia in the United States: a report from the Patterns of Care program , 2014, Leukemia & lymphoma.

[12]  C. Batt,et al.  Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer , 2014, Cancer Immunology Research.

[13]  S. Parmar,et al.  Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents , 2013, Leukemia.

[14]  F. Dammacco,et al.  MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. , 2013, Journal of the National Cancer Institute.

[15]  J. Mohler,et al.  DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11 , 2013, Epigenetics.

[16]  T. Treasure,et al.  Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  F. Fazio,et al.  Clinical and immunologic responses in melanoma patients vaccinated with MAGE‐A3‐genetically modified lymphocytes , 2013, International journal of cancer.

[18]  Li-li Wang,et al.  Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses , 2013, PloS one.

[19]  M. Maio,et al.  Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide , 2013, Cancer Immunology, Immunotherapy.

[20]  C. Plass,et al.  Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia. , 2013, Leukemia research.

[21]  H. Kantarjian,et al.  Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. , 2012, Blood.

[22]  P. Srivastava,et al.  Neem oil limonoids induces p53-independent apoptosis and autophagy. , 2012, Carcinogenesis.

[23]  Pearlly Yan,et al.  Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. , 2012, Blood.

[24]  A. Abudula,et al.  Post-Transcriptional and Epigenetic Regulation of Antigen Processing Machinery (APM) Components and HLA-I in Cervical Cancers from Uighur Women , 2012, PloS one.

[25]  J. Allison,et al.  Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans , 2012, The Journal of Immunology.

[26]  B. Fox,et al.  Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma , 2012, Gene Therapy.

[27]  C. Morrison,et al.  Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients , 2012, Proceedings of the National Academy of Sciences.

[28]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[29]  K. Döhner,et al.  A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy , 2012, Haematologica.

[30]  C. Bokemeyer,et al.  Cancer‐testis antigen expression and its epigenetic modulation in acute myeloid leukemia , 2011, American journal of hematology.

[31]  J. Marshall,et al.  A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors , 2011, Journal of immunotherapy.

[32]  R. Morgan,et al.  Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. , 2011, Cancer research.

[33]  D. Munn,et al.  Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. , 2011, Blood.

[34]  K. Odunsi,et al.  Coordinated Cancer Germline Antigen Promoter and Global DNA Hypomethylation in Ovarian Cancer: Association with the BORIS/CTCF Expression Ratio and Advanced Stage , 2011, Clinical Cancer Research.

[35]  D. Munn,et al.  Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. , 2010, Blood.

[36]  J. Karbach,et al.  The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. , 2010, Leukemia research.

[37]  K. Odunsi,et al.  Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. , 2010, Future oncology.

[38]  Chris A. Nasrallah,et al.  Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. , 2009, Blood.

[39]  T. Gajewski,et al.  PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. , 2009, Blood.

[40]  L. Klein-Hitpass,et al.  Aberrant hypomethylation of the cancer–testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia , 2008, Annals of Hematology.

[41]  K. Odunsi,et al.  Intertumor and Intratumor NY-ESO-1 Expression Heterogeneity Is Associated with Promoter-Specific and Global DNA Methylation Status in Ovarian Cancer , 2008, Clinical Cancer Research.

[42]  M. Herlyn,et al.  Cancer testis antigens in human melanoma stem cells: Expression, distribution, and methylation status , 2008, Journal of Cellular Physiology.

[43]  T. Tomasi,et al.  Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells , 2008, Cancer Immunology, Immunotherapy.

[44]  C. Bokemeyer,et al.  Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. , 2007, Blood.

[45]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[46]  J. Issa,et al.  DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. , 2006, Cancer research.

[47]  K. Pantel,et al.  Promoter Demethylation and Histone Acetylation Mediate Gene Expression of MAGE-A1, -A2, -A3, and -A12 in Human Cancer Cells , 2006, Molecular Cancer Research.

[48]  M. Aoe,et al.  XAGE-1 Expression in Non–Small Cell Lung Cancer and Antibody Response in Patients , 2005, Clinical Cancer Research.

[49]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[50]  C. Bloomfield,et al.  Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  A. Banham,et al.  A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. , 2010, Cancer immunity.

[52]  J. Rowe.  Optimal induction and post-remission therapy for AML in first remission. , 2009, Hematology. American Society of Hematology. Education Program.

[53]  Thomas D. Schmittgen,et al.  Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 2 DD C T Method , 2022 .